HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

(2R,3Z)- N- (1- hydroxyoctadec- 3- en- 2- yl)pivalamide

Also Known As:

DM 102; DM102

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - (2R,3Z)-N-(1-hydroxyoctadec-3-en-2-yl)pivalamide: 2
Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - (2R,3Z)-N-(1-hydroxyoctadec-3-en-2-yl)pivalamide: 2

Experts

1.	Cabot, Myles C: 2 articles (06/2012 - 07/2011)
2.	Casas, Josefina: 2 articles (06/2012 - 07/2011)
3.	Delgado, Antonio: 2 articles (06/2012 - 07/2011)
4.	Fabriás, Gemma: 2 articles (06/2012 - 07/2011)
5.	Flowers, Margaret: 2 articles (06/2012 - 07/2011)
6.	Abad, Jose Luis: 1 article (06/2012)
7.	Gouazé-Andersson, Valérie: 1 article (07/2011)
8.	Karimi, Ramin: 1 article (07/2011)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 07/01/2011 - "The 4-HPR/DM102 combination also elicited synergistic cytotoxicity in DU 145 cells, another human hormone-refractory prostate cancer cell line. " 07/01/2011 - "The purpose of this study was to determine whether the therapeutic efficacy of fenretinide (4-HPR), a ceramide-generating anticancer agent, could be enhanced in prostate cancer cells by inclusion of a novel synthetic acid ceramidase (AC) inhibitor, DM102, a pivaloylamide of a 2-substituted aminoethanol. "
2.	Breast Neoplasms (Breast Cancer) 06/01/2012 - "Cultured breast cancer cells were treated with DM102 [(2R,3Z)-N-(1-hydroxyoctadec-3-en-2-yl)pivalamide, C6-cer, or the combination. " 06/01/2012 - "These data support the effectiveness of targeting AC in combination with exogenous short-chain ceramide as an anticancer strategy, and warrant continued investigation into the utility of the C6-cer/DM102 drug duo in human breast cancer."

Related Drugs and Biologics

1.	Ceramides
2.	Acid Ceramidase
3.	Fenretinide
4.	Antineoplastic Agents (Antineoplastics)
5.	Hormones (Hormone)